Multimodal Analysis of Endomyocardial Biopsies

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorUniversity Hospital, Essen

About this trial

The goal of this observational study is to pursue a multimodal approach to identify the molecular signatures and immune signalling molecules of various myocardial diseases and thereby contribute to improving diagnosis and therapy.

The main aim is:

-Identification of molecular profiles (e.g., proteome, lipidome, metabolome) and immune signalling profiles that are specifically associated with different myocardial diseases and the post-heart transplantation course.

Participants already receiving an endomyocardial biopsy as part of their regular medical care will be enrolled. An additional biopsy sample will be taken for the above mentioned research.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Patients aged >18 years with a clinical indication for endomyocardial biopsy.

Patients capable of providing informed consent who have signed the consent form for participation in the study.

Disqualifiers

Patients without a clinical indication for endomyocardial biopsy (EMB).

Pregnant individuals.

Patients incapable of providing informed consent.

Women of childbearing potential who are not using adequate contraception.

Trial population

All patients receiving an endomyocardial biopsy after routine clinical indication will be enrolled. The identification of molecular profiles from the obtained endomyocardial biopsies (EMBs) represents an exploratory research approach that does not allow for an exact sample size calculation. Considering the heterogeneity of the collected EMBs, and particularly the fact that EMBs are often performed for the differential diagnosis of various rare myocardial diseases, an adequately large study population is necessary to capture rare phenotypes. The planned cohort will include 40 patients each from the main groups: unclear cardiomyopathy, suspected (ICI-)myocarditis, suspected cardiac storage disease, and post-heart transplantation surveillance. Thus, a total of 160 EMBs are targeted for multi-omics analysis.The secondary endpoint of the study allows for a sample size estimation of 56 EMBs for the subgroup of cardiac amyloidosis (calculation according to the full proposal).

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

Not listed

Trial groups

216 Participants
are grouped into 1 trial group
Group A: Patients undergoing endomyocardial biopsy following clinical indication

Trial outcomes

Primary outcomes

1

Spatial molecular profiles and immune signalling in all included patients

Identification of spatial molecular profiles (e.g., proteomic, lipidomic, and metabolomic signatures) and immune signalling pathways specifically associated with various myocardial diseases and post-heart transplantation outcomes.

Time frame
Baseline, up to 1 year

Secondary outcomes

1

Tracer-Uptakes in cardiac amyloidosis.

Ex vivo analysis of tracer uptake in human endomyocardial biopsy samples from patients with cardiac amyloidosis.

Time frame
Baseline, up to 1 year.

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.